Improve PAD PERformance With METformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 202 participants.

Also called NCT03054519

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 202 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03054519
Main results
  • Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease: The PERMET Randomized Clinical Trial JAMA, 2026-02-03 DOI, PubMed 41205146, PMC12596744 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03054519. Randomized; quadruple masking; primary purpose treatment. Start 2017-05-23 (actual); primary completion 2025-08-20 (actual). Results posted on 2026-08-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Improve PAD PERformance With METformin
Acronym
PERMET
Condition
Peripheral Artery Disease
Intervention (Drug)
Metformin
Intervention (Drug)
Placebo
Lead sponsor
Northwestern University (class: other)

Record details

Record id
cardio:ct-nct03054519
Content hash
dd30c8252b780b72383efb93a35ecadc9c3229755fe645b5cf9c034a855bfb46